CIK 0000875320
- Large accelerated filer
VERTEX PHARMACEUTICALS INC / MA
Sign in to watch- Ticker
- VRTX
- Exchange
- Nasdaq
- Industry
- Pharmaceutical Preparations
- FY end
- Dec 31
- Incorporated
- MA
- Entity type
- Operating
- EIN
- 043039129
- Phone
- +1 617-341-6393
- Business address
- 50 NORTHERN AVENUE, BOSTON, MA, 02210
- Open-market buys, last 90 days
- $0
- in 0 filings
- Open-market sales, last 90 days
- $15,378,206
- in 4 filings, $15.4M under 10b5-1 plans
Net −$15,378,206. Shares bought or sold at a price by officers, directors and 10% owners (Form 4 codes P and S). Grants, option exercises and tax withholding aren't counted.
Who's trading
90 days
Reading 100 more Form 4s from the SEC; this list fills in as they're read.
| Date | Insider | Transaction | Shares | Price | Value | Owned after |
|---|---|---|---|---|---|---|
| 2023-04-27 | Kewalramani Reshma CEO & President | Sale 10b5-1 | −1,668 | $339.43 | $566K | 126,690 |
| 2023-04-27 | Kewalramani Reshma CEO & President | Sale 10b5-1 | −38 | $340.19 | $13K | 126,652 |
| 2023-04-14 | SACHS BRUCE I Director | Grant or award · Deferred Stock Units | +131.47 | $332.77 | $44K | 14,400.25 |
| 2023-04-14 | MCKENZIE DIANA Director | Grant or award · Deferred Stock Units | +90.15 | $332.77 | $30K | 3,117.52 |
| 2023-04-13 | SACHS BRUCE I Director | Gift 10b5-1 | −1,210 | 40,000 | ||
| 2023-04-12 | Sanna Bastiano EVP, Cell & Genetic Therapies | Sale 10b5-1 | −874 | $325.70 | $285K | 46,406 |
| 2023-04-12 | Sanna Bastiano EVP, Cell & Genetic Therapies | Sale 10b5-1 | −4,068 | $326.45 | $1.3M | 42,338 |
| 2023-04-12 | Sanna Bastiano EVP, Cell & Genetic Therapies | Sale 10b5-1 | −2,625 | $327.43 | $860K | 39,713 |
| 2023-04-12 | SACHS BRUCE I Director | Exercise or conversion 10b5-1 | +21,300 | $72.14 | $1.5M | 62,510 |
| 2023-04-12 | SACHS BRUCE I Director | Sale 10b5-1 | −2,917 | $325.65 | $950K | 59,593 |
| 2023-04-12 | SACHS BRUCE I Director | Sale 10b5-1 | −10,357 | $326.46 | $3.4M | 49,236 |
| 2023-04-12 | SACHS BRUCE I Director | Sale 10b5-1 | −8,026 | $327.48 | $2.6M | 41,210 |
| 2023-04-12 | SACHS BRUCE I Director | Exercise or conversion · Stock Option (Right to Buy) 10b5-1 | −21,300 | 0 | ||
| 2023-04-04 | Sanna Bastiano EVP, Cell & Genetic Therapies | Sale 10b5-1 | −211 | $314.22 | $66K | 47,591 |
| 2023-04-04 | Sanna Bastiano EVP, Cell & Genetic Therapies | Sale 10b5-1 | −94 | $315.66 | $30K | 47,497 |
| 2023-04-04 | Sanna Bastiano EVP, Cell & Genetic Therapies | Sale 10b5-1 | −90 | $316.76 | $29K | 47,407 |
| 2023-04-04 | Sanna Bastiano EVP, Cell & Genetic Therapies | Sale 10b5-1 | −96 | $317.65 | $30K | 47,311 |
| 2023-04-04 | Sanna Bastiano EVP, Cell & Genetic Therapies | Sale 10b5-1 | −31 | $318.68 | $10K | 47,280 |
| 2023-03-31 | Sanna Bastiano EVP, Cell & Genetic Therapies | Shares withheld for taxes | −1,466 | $313.74 | $460K | 47,802 |
| 2023-03-31 | Ambrose Kristen SVP & Chief Accounting Officer | Shares withheld for taxes | −176 | $313.74 | $55K | 7,127 |
Page 31 of 40 · 781 trades